FINE FOODS & PHARMACEUTICALS (FF.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:FF - IT0005215329 - Common Stock
9.24 EUR
-0.14 (-1.49%)
We assign a fundamental rating of 5 out of 10 to FF. FF was compared to 22 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of FF get a neutral evaluation. Nothing too spectacular is happening here. FF is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year FF was profitable.
In the past year FF had a positive cash flow from operations.
In multiple years FF reported negative net income over the last 5 years.
Of the past 5 years FF 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of FF (6.89%) is better than 77.27% of its industry peers.
Looking at the Return On Equity, with a value of 13.58%, FF belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
FF's Return On Invested Capital of 9.84% is amongst the best of the industry. FF outperforms 81.82% of its industry peers.
FF had an Average Return On Invested Capital over the past 3 years of 3.16%. This is significantly below the industry average of 9.70%.
The 3 year average ROIC (3.16%) for FF is below the current ROIC(9.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 13.58% | ||
| ROIC | 9.84% |
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
1.3 Margins
FF's Profit Margin of 5.07% is on the low side compared to the rest of the industry. FF is outperformed by 68.18% of its industry peers.
The Operating Margin of FF (7.85%) is worse than 77.27% of its industry peers.
In the last couple of years the Operating Margin of FF has grown nicely.
FF has a Gross Margin (34.77%) which is comparable to the rest of the industry.
FF's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.85% | ||
| PM (TTM) | 5.07% | ||
| GM | 34.77% |
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so FF is still creating some value.
Compared to 1 year ago, FF has about the same amount of shares outstanding.
The number of shares outstanding for FF has been increased compared to 5 years ago.
FF has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.04 indicates that FF is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.04, FF is in line with its industry, outperforming 54.55% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that FF is not too dependend on debt financing.
The Debt to Equity ratio of FF (0.44) is better than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.04 |
ROIC/WACC1.09
WACC9.03%
2.3 Liquidity
A Current Ratio of 1.67 indicates that FF should not have too much problems paying its short term obligations.
FF has a Current ratio of 1.67. This is amongst the best in the industry. FF outperforms 81.82% of its industry peers.
FF has a Quick Ratio of 1.07. This is a normal value and indicates that FF is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.07, FF perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
FF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 147.03%, which is quite impressive.
The Revenue has been growing slightly by 1.78% in the past year.
Measured over the past years, FF shows a quite strong growth in Revenue. The Revenue has been growing by 8.83% on average per year.
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
3.2 Future
The Earnings Per Share is expected to grow by 27.39% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.10% on average over the next years. This is quite good.
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue Next Year5.61%
Revenue Next 2Y9.55%
Revenue Next 3Y9.52%
Revenue Next 5Y12.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.38, which indicates a very decent valuation of FF.
95.45% of the companies in the same industry are more expensive than FF, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.92, FF is valued rather cheaply.
With a Price/Forward Earnings ratio of 13.16, FF is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FF indicates a rather cheap valuation: FF is cheaper than 95.45% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.57. FF is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.38 | ||
| Fwd PE | 13.16 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than FF, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 5.79 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FF's earnings are expected to grow with 29.85% in the coming years.
PEG (NY)0.19
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y29.85%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.46%, FF has a reasonable but not impressive dividend return.
FF's Dividend Yield is rather good when compared to the industry average which is at 0.48. FF pays more dividend than 95.45% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 1.94, FF is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.46% |
5.2 History
The dividend of FF has a limited annual growth rate of 4.24%.
Dividend Growth(5Y)4.24%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
18.40% of the earnings are spent on dividend by FF. This is a low number and sustainable payout ratio.
FF's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP18.4%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
BIT:FF (1/7/2026, 7:00:00 PM)
9.24
-0.14 (-1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners12%
Inst Owner ChangeN/A
Ins Owners53.17%
Ins Owner ChangeN/A
Market Cap203.83M
Revenue(TTM)373.66M
Net Income(TTM)18.62M
Analysts85.45
Price Target12.51 (35.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.46% |
Yearly Dividend0.12
Dividend Growth(5Y)4.24%
DP18.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)13.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.38 | ||
| Fwd PE | 13.16 | ||
| P/S | 0.56 | ||
| P/FCF | N/A | ||
| P/OCF | 5.52 | ||
| P/B | 1.49 | ||
| P/tB | 1.64 | ||
| EV/EBITDA | 5.79 |
EPS(TTM)0.89
EY9.63%
EPS(NY)0.7
Fwd EY7.6%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)1.67
OCFY18.1%
SpS16.64
BVpS6.22
TBVpS5.62
PEG (NY)0.19
PEG (5Y)N/A
Graham Number11.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 13.58% | ||
| ROCE | 14.28% | ||
| ROIC | 9.84% | ||
| ROICexc | 11.04% | ||
| ROICexgc | 11.92% | ||
| OM | 7.85% | ||
| PM (TTM) | 5.07% | ||
| GM | 34.77% | ||
| FCFM | N/A |
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
ROICexc(3y)3.64%
ROICexc(5y)4.57%
ROICexgc(3y)4.02%
ROICexgc(5y)5.02%
ROCE(3y)4.59%
ROCE(5y)4.62%
ROICexgc growth 3Y13.05%
ROICexgc growth 5Y-1.19%
ROICexc growth 3Y17.44%
ROICexc growth 5Y-2.63%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
F-Score7
Asset Turnover1.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.35 | ||
| Cap/Depr | 262.56% | ||
| Cap/Sales | 11.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 82.61% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 3.04 |
F-Score7
WACC9.03%
ROIC/WACC1.09
Cap/Depr(3y)145.26%
Cap/Depr(5y)138.08%
Cap/Sales(3y)9.82%
Cap/Sales(5y)9.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
Revenue Next Year5.61%
Revenue Next 2Y9.55%
Revenue Next 3Y9.52%
Revenue Next 5Y12.1%
EBIT growth 1Y70.93%
EBIT growth 3Y34.65%
EBIT growth 5Y11.14%
EBIT Next Year142.69%
EBIT Next 3Y46.91%
EBIT Next 5Y31.96%
FCF growth 1Y57.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y568.5%
OCF growth 3YN/A
OCF growth 5Y19.07%
FINE FOODS & PHARMACEUTICALS / FF.MI FAQ
What is the fundamental rating for FF stock?
ChartMill assigns a fundamental rating of 5 / 10 to FF.MI.
Can you provide the valuation status for FINE FOODS & PHARMACEUTICALS?
ChartMill assigns a valuation rating of 6 / 10 to FINE FOODS & PHARMACEUTICALS (FF.MI). This can be considered as Fairly Valued.
Can you provide the profitability details for FINE FOODS & PHARMACEUTICALS?
FINE FOODS & PHARMACEUTICALS (FF.MI) has a profitability rating of 5 / 10.
Can you provide the financial health for FF stock?
The financial health rating of FINE FOODS & PHARMACEUTICALS (FF.MI) is 5 / 10.
Can you provide the expected EPS growth for FF stock?
The Earnings per Share (EPS) of FINE FOODS & PHARMACEUTICALS (FF.MI) is expected to grow by 53.89% in the next year.